Pipeline

Products under development

Treatment
field
Pipeline source of technology Mechanism Target
indication
Preclinical
studies
IND
Declaration
Clinical Trial
PhaseⅠ
Clinical Trial
Phase Ⅱ
Clinical Trial
Phase Ⅲ
rights
interests
 
Metabolic diseases PB-119 Independent R D a long-acting GLP-1 receptor agonist type 2 diabetes mellitus
Global
Metabolic diseases PB-201 授权引进 glucokinase activator (GKA) type 2 diabetes mellitus
Greater China
Metabolic diseases PB-718 Independent R D a dual agonist that activates both the GLP-1 receptor and the glucagon receptor nonalcoholic fatty liver disease
Global
Metabolic diseases PB-119 Independent R D a long-acting GLP-1 receptor agonist overweight or obesity
Global
Metabolic diseases PB-718 Independent R D a dual agonist that activates both the GLP-1 receptor and the glucagon receptor overweight or obesity
Global
Metabolic diseases PB-1802 Independent R D uricase tumor lysis syndrome and refractory gout
Global
Gastrointestinal diseases PB-1902 Independent R D the only oral opioid receptor antagonist for the treatment of opioid-induced constipation (OIC) opioid-induced constipation
Global
other Metabolic diseases PB-722 Independent R D GCG receptor agonist a novel drug for congenital hyperinsulinemia
Global

Product development strategy